Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Optimizing Early Breast Cancer Outcomes in the Community Setting: An Expert Review of Emerging Therapies and Evolving Standards of Care in HR+/HER2- Disease

1:01:59
 
Share
 

Manage episode 347104804 series 2870185
Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ebc-gr-podcast

Learning Objectives

  • Review the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk of disease recurrence as a means of guiding treatment.
  • Appraise the current treatment landscape in HR+, HER2- EBC, including the established and emerging evidentiary base for novel therapies in the adjuvant setting, expert consensus guidelines, and FDA-approved indications.
  • Recognize treatment-related adverse events associated with oral therapies used in HR+, HER2- EBC and implement evidence-supported mitigation and management protocols.
  • Using real-world patient case examples, design on-label treatment plans for HR+, HER2- EBC at high risk for recurrence, emphasizing the critical need for effective communication and coordination strategies among the multidisciplinary community-based breast cancer care team.
  • Evaluate adaptive approaches for promoting adherence and persistence to oral anticancer therapies, highlighting common reasons for noncompliance and the impact of patient counseling and shared decision-making (SDM).

Presented by:
Hope S. Rugo, MD
Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from Lilly.

  continue reading

35 episodes

Artwork
iconShare
 
Manage episode 347104804 series 2870185
Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/ebc-gr-podcast

Learning Objectives

  • Review the epidemiology and clinical characteristics of HR+, HER2- early-breast cancer (EBC), and identify patients at an elevated risk of disease recurrence as a means of guiding treatment.
  • Appraise the current treatment landscape in HR+, HER2- EBC, including the established and emerging evidentiary base for novel therapies in the adjuvant setting, expert consensus guidelines, and FDA-approved indications.
  • Recognize treatment-related adverse events associated with oral therapies used in HR+, HER2- EBC and implement evidence-supported mitigation and management protocols.
  • Using real-world patient case examples, design on-label treatment plans for HR+, HER2- EBC at high risk for recurrence, emphasizing the critical need for effective communication and coordination strategies among the multidisciplinary community-based breast cancer care team.
  • Evaluate adaptive approaches for promoting adherence and persistence to oral anticancer therapies, highlighting common reasons for noncompliance and the impact of patient counseling and shared decision-making (SDM).

Presented by:
Hope S. Rugo, MD
Professor, Division of Hematology/Oncology
Director, Breast Oncology Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from Lilly.

  continue reading

35 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play